unknown
Stage
2023
Founded
1
Investors
About
Hemispherian is a clinical-stage pharmaceutical company developing novel small molecule drugs targeting the TET2 enzyme to treat aggressive cancers such as glioblastoma by restoring cancer cells' normal epigenetic complement and triggering DNA damage response.
Explore Hemispherian's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.